Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pegram

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II StudyNancy U Lin, Mark Pegram, Solmaz Sahebjam, et al.
NPJ Breast Cancer|November 18, 2023
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy dataNancy U Lin, Priya Kumthekar, Solmaz Sahebjam, et al.
Breast Cancer Research : BCR|March 17, 2016
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerIan E Krop, Shanu Modi, Patricia M LoRusso, et al.
Molecular Cancer Therapeutics|December 13, 2002
Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 inductionSaskia T C Neuteboom, Patricia L Karjian, Christopher R Boyer, et al.
Cancer Immunology Research|July 4, 2014
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831Nadine Norton, Rebecca M Olson, Mark Pegram, et al.
Oncology and Therapy|November 14, 2025
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast CancerSarah Sammons, Denise A Yardley, Priyanka Sharma, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancerXavier Pivot, Mark Pegram, Javier Cortes, et al.
Cancer Metastasis Reviews|June 14, 2006
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agentsJocelyn Holash, Gavin Thurston, John S Rudge, et al.
Clinical Breast Cancer|December 15, 2010
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancerKathy S Albain, Lisa Carey, William J Gradishar, et al.
Cancer Gene Therapy|June 26, 2002
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerRichard E Buller, Ingo B Runnebaum, Beth Y Karlan, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II StudyNancy U Lin, Mark Pegram, Solmaz Sahebjam, et al.
NPJ Breast Cancer|November 18, 2023
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy dataNancy U Lin, Priya Kumthekar, Solmaz Sahebjam, et al.
Breast Cancer Research : BCR|March 17, 2016
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerIan E Krop, Shanu Modi, Patricia M LoRusso, et al.
Molecular Cancer Therapeutics|December 13, 2002
Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 inductionSaskia T C Neuteboom, Patricia L Karjian, Christopher R Boyer, et al.
Cancer Immunology Research|July 4, 2014
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831Nadine Norton, Rebecca M Olson, Mark Pegram, et al.
Oncology and Therapy|November 14, 2025
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast CancerSarah Sammons, Denise A Yardley, Priyanka Sharma, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancerXavier Pivot, Mark Pegram, Javier Cortes, et al.
Cancer Metastasis Reviews|June 14, 2006
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agentsJocelyn Holash, Gavin Thurston, John S Rudge, et al.
Clinical Breast Cancer|December 15, 2010
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancerKathy S Albain, Lisa Carey, William J Gradishar, et al.
Cancer Gene Therapy|June 26, 2002
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerRichard E Buller, Ingo B Runnebaum, Beth Y Karlan, et al.
Pageof 7